Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07816692

iDose TR Administration in an Office-Based Surgery Setting

Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Open Angle Glaucoma (OAG) Eye Diseases Glaucoma Glaucoma, Open-Angle Ocular Hypertension Ocular Hypertension (OHT)

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Glaukos Investigative Site

Austin, Texas, 78746, United States

Location status: Recruiting

Location contact

Glaukos Investigative Site

CONTACT

[email protected]

949-739-8749

About this study

This study is a multicenter, single arm, open-label trial in adult subjects with open-angle glaucoma or ocular hypertension. The objective of the study is to assess the safety profile of iDose TR administration in an office-based surgery setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT)

Exclusion criteria

  • Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye Active ocular infection or inflammation History of hypersensitivity to travoprost or implant components Recent ocular surgery Uncontrolled systemic disease Any condition preventing safe implantation

Treatment and study plan

iDose TR (travoprost intracameral implant) 75 µg

Combination Product

Travoprost-releasing implant preloaded in a sterile, single-use inserter.

Other names: iDose TR

Primary outcomes

  1. Successful administration of iDose TR in an office-based surgical setting.

    Time frame: 3 months

    Number of subjects that received iDose TR in an office-based surgical setting by the Investigator.

Study contacts

Contact information is provided by the study sponsor or research team.

Study Director

CONTACT

[email protected]

949-739-8749

Sponsors and collaborators

Lead sponsor

Glaukos Corporation

Industry

Registry information

Official study title

Real-World Evidence Observational Study to Evaluate the Safety of iDose® TR (Travoprost Intracameral Implant) 75 µg in an Office-Based Surgery Setting

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Sep 14, 2026
Registry last updated
Sep 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.